EYPT Relative Valuation
EYPT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EYPT is overvalued; if below, it's undervalued.
Historical Valuation
EyePoint Pharmaceuticals Inc (EYPT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.37. The fair price of EyePoint Pharmaceuticals Inc (EYPT) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：16.72
Fair
-6.05
PE
1Y
3Y
5Y
Trailing
Forward
-23.62
EV/EBITDA
EyePoint Pharmaceuticals Inc. (EYPT) has a current EV/EBITDA of -23.62. The 5-year average EV/EBITDA is -0.94. The thresholds are as follows: Strongly Undervalued below -15.29, Undervalued between -15.29 and -8.12, Fairly Valued between 6.23 and -8.12, Overvalued between 6.23 and 13.40, and Strongly Overvalued above 13.40. The current Forward EV/EBITDA of -23.62 falls within the Strongly Undervalued range.
-4.07
EV/EBIT
EyePoint Pharmaceuticals Inc. (EYPT) has a current EV/EBIT of -4.07. The 5-year average EV/EBIT is -1.56. The thresholds are as follows: Strongly Undervalued below -9.27, Undervalued between -9.27 and -5.42, Fairly Valued between 2.30 and -5.42, Overvalued between 2.30 and 6.16, and Strongly Overvalued above 6.16. The current Forward EV/EBIT of -4.07 falls within the Historic Trend Line -Fairly Valued range.
544.96
PS
EyePoint Pharmaceuticals Inc. (EYPT) has a current PS of 544.96. The 5-year average PS is 28.86. The thresholds are as follows: Strongly Undervalued below -142.70, Undervalued between -142.70 and -56.92, Fairly Valued between 114.64 and -56.92, Overvalued between 114.64 and 200.42, and Strongly Overvalued above 200.42. The current Forward PS of 544.96 falls within the Strongly Overvalued range.
-6.08
P/OCF
EyePoint Pharmaceuticals Inc. (EYPT) has a current P/OCF of -6.08. The 5-year average P/OCF is -2.25. The thresholds are as follows: Strongly Undervalued below -19.21, Undervalued between -19.21 and -10.73, Fairly Valued between 6.23 and -10.73, Overvalued between 6.23 and 14.71, and Strongly Overvalued above 14.71. The current Forward P/OCF of -6.08 falls within the Historic Trend Line -Fairly Valued range.
-6.31
P/FCF
EyePoint Pharmaceuticals Inc. (EYPT) has a current P/FCF of -6.31. The 5-year average P/FCF is -2.86. The thresholds are as follows: Strongly Undervalued below -22.34, Undervalued between -22.34 and -12.60, Fairly Valued between 6.88 and -12.60, Overvalued between 6.88 and 16.62, and Strongly Overvalued above 16.62. The current Forward P/FCF of -6.31 falls within the Historic Trend Line -Fairly Valued range.
EyePoint Pharmaceuticals Inc (EYPT) has a current Price-to-Book (P/B) ratio of 5.81. Compared to its 3-year average P/B ratio of 3.24 , the current P/B ratio is approximately 79.43% higher. Relative to its 5-year average P/B ratio of 3.40, the current P/B ratio is about 70.70% higher. EyePoint Pharmaceuticals Inc (EYPT) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -20.15%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -18.06% , the current FCF yield is about -100.00% lower.
5.81
P/B
Median3y
3.24
Median5y
3.40
-17.77
FCF Yield
Median3y
-20.15
Median5y
-18.06
Competitors Valuation Multiple
The average P/S ratio for EYPT's competitors is 0.00, providing a benchmark for relative valuation. EyePoint Pharmaceuticals Inc Corp (EYPT) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -90.82%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of EYPT increased by 124.43% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -278.99 to -6.18K.
The secondary factor is the Revenue Growth, contributed -90.82%to the performance.
Overall, the performance of EYPT in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is EyePoint Pharmaceuticals Inc (EYPT) currently overvalued or undervalued?
What is EyePoint Pharmaceuticals Inc (EYPT) fair value?
How does EYPT's valuation metrics compare to the industry average?
What is the current P/B ratio for EyePoint Pharmaceuticals Inc (EYPT) as of Dec 05 2025?
What is the current FCF Yield for EyePoint Pharmaceuticals Inc (EYPT) as of Dec 05 2025?
What is the current Forward P/E ratio for EyePoint Pharmaceuticals Inc (EYPT) as of Dec 05 2025?